Ding is a nine-year veteran of Astellas.
Wolfe Research analysts say the market is underestimating the vaccine’s potential by more than $2 billion.
Xeomin, made by Merz, is hoping to differentiate itself in a market dominated by Allergan’s Botox.
National ad spend grew 7% year-over-year across all categories and platforms including pharma in October.
Robert Zirkelbach, public affairs EVP at PhRMA, discussed the group’s legislative priorities at the Coalition for Healthcare Communication’s post-election conference on Tuesday.
The drugmaker will raise prices on 10% of its drug portfolio.
The Trump administration has proposed basing Medicare Part B drug prices on what other countries pay.
The drugmaker has refocused on ethics to move past the Michael Cohen scandal.
Teva’s Ajovy becomes the second approved CGRP migraine therapy, following Amgen’s Aimovig.
Sprout’s controversial sexual-desire drug receives FDA approval; prescription-drug coverage impacts cash sales at Walmart; Mylan warned about manufacturing violations
Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.
Talking Medicines’ Jo Halliday discussed how the pharmaceutical sector can better understand the voice of the patient.
Learn about Intouch Group’s journey to foster I+D so that its inclusive culture translates into inclusive healthcare marketing.
Any EHR provider delivering a quality solution should be able to answer these six questions.
Veradigm VP Damon Basch sits down to discuss strategy for point of care media in the age of Covid-19.
Please login or register first to view this content.